Raised full-year 2026 outlook lifts Abbott stock 3.18%

Traders Union
All News
Financial News
Abbott surges 3.18% to $87.16 today

Highlights

Abbott delivered higher Q1 2026 earnings, propelled by robust diabetes care and medical device sales momentum.
Management raised full-year earnings guidance, signaling operational confidence as institutional investors expand positions and the company prioritizes R&D and shareholder returns.
Technically, the stock remains under pressure below key resistance amid continued bearish momentum, with an outlook for rangebound trade between $84.50 and $89.00.

Earnings beat and guidance raise fuel investor interest

Abbott has posted higher earnings for the first quarter of 2026, driven by strong growth in its diabetes care and medical devices segments, which is contributing to renewed investor demand. The company has also raised its full-year earnings guidance, reflecting confidence in its operational outlook and strengthening its appeal in the current market environment. Alongside these results, Abbott maintained its regular capital returns with a mid-May quarterly dividend payment of $0.63 per share and saw several institutional investors increase their holdings, while continuing to prioritize investment in research, targeted acquisitions, and shareholder distributions.

Oversold signals clash with strong bearish momentum below resistance

ABT currently trades below the SMA-20 at $88.74, SMA-50 at $98.29, and SMA-200 at $118.54. The Ichimoku Kijun sits at $92.37, acting as immediate resistance. The MACD and ADX both show strong bearish momentum. RSI, CCI, and Bull/Bear Power (BBP) all indicate oversold conditions, with BBP registering −0.64, reflecting pronounced seller dominance intraday. There was no visible opening gap, and ABT closed near its session highs, exhibiting moderate volatility and firm buying into the close. However, technical divergence is apparent between oversold oscillators and persistent downside momentum.

Downside risk persists as breakout unlikely without fresh catalyst

For the coming week, ABT is projected to fluctuate within a typical volatility band of $84.50 to $89.00. With the probability of a further price increase assessed at less than 20%, continued downward movement remains the more likely scenario. The base case calls for ABT to stay below major resistance, with the possibility of remaining rangebound. Bulls would need a break above $92.37 to shift momentum, while increased selling pressure could trigger a test and potential breach of support at $84.50.

Viktoras Karapetjanc, analyst at Traders Union, sees strong earnings momentum and upgraded guidance as a solid foundation for Abbott's long-term value. He believes institutional inflows and continued capital returns provide a constructive backdrop, despite technical pressures in the short term. However, persistent bearish momentum and resistance levels require caution for immediate upside. "While short-term price action remains capped, improving fundamentals and investor confidence keep my outlook positive if resistance at $92.37 is reclaimed."

Earlier, analysts noted that Abbott Laboratories was experiencing persistent bearish momentum, with technical weakness outweighing pockets of fundamental strength. The current analysis reinforces this view and suggests that until ABT decisively reclaims resistance above $92.37, traders should remain alert to the heightened risk of another test of support in the near term.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.